Circle Pharma Secures $90 Million Series D for Oral Macrocycle Therapies

Circle Pharma, a biopharmaceutical company located in South San Francisco, has completed a successful Series D financing round, raising $90 million. This round included the conversion of a convertible note and was led by The Column Group. Other participants included both new and existing investors such as Nextech Invest and Euclidean Capital. 

The raised funds will primarily be used to support the clinical development of CID-078, which is Circle Pharma’s unique cyclin A/B RxL inhibitor. Additionally, some proceeds will be allocated to advance the company’s portfolio of discovery programs that utilize its MXMO macrocycle platform. 

David Earp, JD, Ph.D., and CEO of Circle Pharma expressed his gratitude for the robust investor support. He emphasized that the financing will enable the company to advance CID-078 through essential clinical development stages while also pushing forward their pipeline of innovative therapies aimed at treating cancer and other severe diseases.

With this fresh influx of capital, Circle Pharma is strategically positioned to make significant progress toward its goal of developing effective treatments for cancer and other critical illnesses.

Circle Pharma, Inc. is focused on pioneering the discovery and development of cell-permeable macrocycles that can be administered through various routes, including orally. The company's MXMO™ platform integrates structure-based rational drug design with advanced synthetic chemistry to create a new generation of macrocycle therapies that target difficult-to-address clinical needs. Their primary focus is on cyclins, which are crucial regulators of cellular progression and key contributors to many cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!